Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President
January 06 2020 - 7:30AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced the appointment of Dara Grantham Wright as Executive Vice
President and President of the Clinical Diagnostics Group,
effective January 1, 2020. She takes the place of John Hertia who
retired from this role on December 31, 2019. Ms. Grantham Wright
will be responsible for providing global leadership and management
of the overall strategy and business direction for the company’s
Clinical Diagnostics Group global operations.
“We are pleased to have Dara join Bio-Rad and believe she will
make an excellent addition to our team,” said Andrew Last, Bio-Rad
Executive Vice President and Chief Operating Officer. “Dara brings
a wealth of experience, business acumen, and a proven track record
of success that make her the ideal person to lead our Clinical
Diagnostics Group. We would also like to thank John for his many
years of valuable contributions to the growth and success of
Bio-Rad, and we wish him the best in his retirement,” Dr. Last
said.
Ms. Grantham Wright most recently was Vice President &
General Manager, Biosciences Division, Life Science Solutions
Group, Protein & Cell Analysis, Thermo Fisher Scientific, the
company’s largest business unit. Prior to Thermo Fisher Scientific,
she was Senior Vice President & General Manager, eBioscience
Business Unit at Affymetrix.
Dara has also served with Boreal Genomics as Chief Commercial
Officer and with Affymetrix as Global Vice President of Strategic
Marketing & Clinical Applications. Prior to Affymetrix, she
spent over 10 years in marketing roles at BD Biosciences.
Ms. Grantham Wright holds a Master’s Degree in Business
Administration from San Diego State University and a Bachelor of
Arts in Biology and Spanish.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding the expected
contributions and benefits of the new officer. We have based these
statements on the information now known to us. Such statements
involve risks and uncertainties, which could cause actual results
to vary materially from those expressed in or indicated by the
forward-looking statements. For further information regarding our
risks and uncertainties, please refer to the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operation” in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
The Company cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and
speak only as of the date hereof. Bio-Rad Laboratories, Inc.
disclaims any obligation to update these forward-looking
statements.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.2 billion in 2018. For more information,
please visit www.bio-rad.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200106005029/en/
Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications
510-724-7000 tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2024 to May 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From May 2023 to May 2024